$-0.90 EPS Expected for Ascendis Pharma A/S (ASND)

March 22, 2018 - By Vivian Park

 $ 0.90 EPS Expected for Ascendis Pharma A/S (ASND)

Analysts expect Ascendis Pharma A/S (NASDAQ:ASND) to report $-0.90 EPS on March, 28.They anticipate $0.35 EPS change or 63.64 % from last quarter’s $-0.55 EPS. After having $-1.22 EPS previously, Ascendis Pharma A/S’s analysts see -26.23 % EPS growth. The stock increased 3.03% or $1.94 during the last trading session, reaching $66.04. About 205,771 shares traded or 4.87% up from the average. Ascendis Pharma A/S (NASDAQ:ASND) has risen 96.01% since March 22, 2017 and is uptrending. It has outperformed by 79.31% the S&P500.

Ascendis Pharma A/S (NASDAQ:ASND) Ratings Coverage

Among 7 analysts covering Ascendis Pharma (NASDAQ:ASND), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Ascendis Pharma has $78 highest and $28.0 lowest target. $54.29’s average target is -17.79% below currents $66.04 stock price. Ascendis Pharma had 21 analyst reports since September 26, 2016 according to SRatingsIntel. The rating was maintained by Credit Suisse on Friday, September 22 with “Outperform”. The company was maintained on Thursday, February 22 by Credit Suisse. The rating was maintained by Bank of America on Thursday, January 25 with “Buy”. As per Thursday, September 28, the company rating was maintained by Wedbush. The firm earned “Buy” rating on Monday, September 11 by Wedbush. Wedbush maintained the shares of ASND in report on Monday, February 26 with “Buy” rating. On Friday, January 5 the stock rating was maintained by Wedbush with “Buy”. Wedbush maintained the stock with “Buy” rating in Friday, September 22 report. The stock of Ascendis Pharma A/S (NASDAQ:ASND) earned “Buy” rating by Wells Fargo on Friday, September 22. Bank of America maintained Ascendis Pharma A/S (NASDAQ:ASND) on Tuesday, September 26 with “Buy” rating.

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. The company has market cap of $2.74 billion. It is developing TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; and TransCon Treprostinil that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. It currently has negative earnings. The firm is also developing TransCon Peptides for the treatment of diabetes; TransCon ranibizumab, a compound to support injection of ranibizumab in ophthalmology; TransCon parathyroid hormone for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

More notable recent Ascendis Pharma A/S (NASDAQ:ASND) news were published by: Globenewswire.com which released: “Ascendis Pharma A/S Reports Second Quarter 2017 Financial Results” on August 18, 2017, also Prnewswire.com with their article: “Ascendis Pharma A/S Reports First Quarter 2017 Financial Results” published on May 23, 2017, Benzinga.com published: “5 Biggest Price Target Changes For Tuesday” on March 20, 2018. More interesting news about Ascendis Pharma A/S (NASDAQ:ASND) were released by: Marketwatch.com and their article: “Ascendis Pharma shares surge 42% on competitor’s flop” published on September 22, 2017 as well as Globenewswire.com‘s news article titled: “Ascendis Pharma Announces Two Posters on Rare Disease Pipeline Programs at …” with publication date: March 19, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: